Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Hims & Hers Surge as ZAVA Acquisition Boosts European Expansion

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 6/27/2025, 11:32 am ET 5 min read
Hims & Hers Surge as ZAVA Acquisition Boosts European Expansion Thumbnail

Hims & Hers Health Inc. stocks have been trading up by 8.51 percent amid increasing investor confidence.

Key Takeaways

  • Near 2% jump seen in premarket hours, reflecting strong positive investor sentiments.
  • Strategic acquisition of ZAVA accelerates market entry into the UK, Germany, France, and Ireland.
  • European digital health platform acquisition expected to be revenue-positive by 2026.
  • Shares of multiple tech firms mark significant movement with HIMS leading the gains.
  • Continues offering weight-loss solutions, emphasizing commitment to affordable healthcare services.

Candlestick Chart

Live Update At 11:32:28 EST: On Friday, June 27, 2025 Hims & Hers Health Inc. stock [NYSE: HIMS] is trending up by 8.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Hims & Hers Health, a prominent player in personalized healthcare, has shown considerable volatility in recent sessions. Analyzing its recent stock performance, it’s evident that the company is on upward trajectory. In a span of just a few days, the stock has oscillated, closing at $50.26 from $46.28 just days earlier. The upward climb is a clear reflection of favorable market sentiment surrounding their strategic initiatives.

More Breaking News

Recently, they posted quarterly revenue close to $586M with an operating income of just under $58M. Deducting taxes, their net income stood firmly at about $49M. One interesting point is the company’s gross margin, which is strikingly high at 77%, an indicator of solid profitability. However, their PE Ratio of 68.06 suggests some areas still require cautious oversight, implying relatively high investor expectations for growth.

Market Reactions

When Hims & Hers announced acquiring the European digital health platform, ZAVA, investors took notice. This acquisition positions the company to tap into a vast demographic in Germany, the UK, France, and Ireland. As the company plans to leverage ZAVA’s established infrastructure, this move is expected to significantly contribute to revenue, anticipated to be accretive by 2026. The financial backing for this purchase will come from HIMS’ cash reserves, showcasing their fiscal robustness.

The market responded positively to this news, with the stock showing a nearly 2% rise in premarket trading. This suggests that this acquisition is viewed as a strategic milestone in their global expansion plans. Beyond the numbers, there’s a certain excitement in the air. Anecdotally, it reminds one of the golden days of tech acquisitions from the early ‘2000s, although this time with healthcare champions of today.

Acquisition Dreams and Market Impact

Why does this move matter in the grander scheme? The healthcare sector is becoming increasingly competitive, with digital integration at the forefront of future strategies. By integrating ZAVA, Hims & Hers can enhance its digital offerings and perhaps pave the path for an innovative virtual healthcare service suite.

Moreover, the shares were buoyant following the affirmation that low-cost, weight-loss solutions will continue despite ending a partnership with Novo Nordisk. This strategy solidifies their promise of accessible, affordable healthcare to their customer base.

On the corporate front, this acquisition might stir ripple effects. It hints at a larger trend where traditional health frameworks might shift towards automated, digital interfaces, potentially reshaping consumer expectations. The newest initiative and focus on expanding their digital foothold in Europe might increase their market share.

Conclusion

In conclusion, Hims & Hers Health’s move to acquire ZAVA signals a forward-thinking adaptation to the rapidly changing landscape of healthcare needs. The stock’s recent movements suggest strong trader confidence and anticipation of future growth. The European market is ripe for disruption, and if this strategic endeavor unfolds as planned, it could widen the gap between Hims & Hers and their competitors.

One might say the entire equity landscape is reminiscent of a chess game, where strategic moves determine standing. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” While speculation is always prevalent, the current state of the market seems to suggest bullish sentiments for HIMS. And if their recent acquisition is anything to go by, the road ahead looks promisingly fruitful, both for the company and its stakeholders.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications